Skip to main content
Erschienen in: Skeletal Radiology 3/2024

21.08.2023 | Case Report

Extranodal Rosai-Dorfman Disease: a rare presentation involving anterior chest wall in a middle-aged female

verfasst von: Abhimanyu Agarwal, Aishwarya Ravindran, James Donahue, Isam-Eldin Eltoum, Mostafa Abozeed

Erschienen in: Skeletal Radiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Rosai-Dorfman Disease is a rare benign disorder involving overproduction of immune cells, causing swollen lymph nodes and, in rare cases, the sternum. The sternal involvement may cause chest pain and masses. Diagnosis is confirmed through clinical examination, biopsy, and imaging. Treatment options may include surgery, radiation, or steroids. In this case study, we present an unusual example of extranodal Rosai-Dorfman Disease involving the sternum, bilateral clavicles and first three ribs, and pectoral muscle with no associated lymphadenopathy or systemic symptoms in a 57-year-old female. The etiology, pathology, immunohistochemistry, imaging findings, and treatment options of this unique disease are discussed.
Glossar
CD
Scluster of differentiation
IHC
Immunohistochemistry
OCT2
Octamer binding transcription factor 2
SUV
standardized uptake value
Literatur
1.
Zurück zum Zitat Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19. https://doi.org/10.1038/s41375-022-01613-1.CrossRefPubMedPubMedCentral Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19. https://​doi.​org/​10.​1038/​s41375-022-01613-1.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d’Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–53. https://doi.org/10.1182/blood.2022015851.CrossRefPubMedCentral Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d’Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–53. https://​doi.​org/​10.​1182/​blood.​2022015851.CrossRefPubMedCentral
3.
Zurück zum Zitat Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM, Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81. https://doi.org/10.1182/blood-2016-01-690636.CrossRefPubMedPubMedCentral Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM, Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81. https://​doi.​org/​10.​1182/​blood-2016-01-690636.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Bruce-Brand C, Schneider JW. Schubert P Rosai-Dorfman Disease: an overview. J Clin Pathol. 2020;73:697–705.CrossRefPubMed Bruce-Brand C, Schneider JW. Schubert P Rosai-Dorfman Disease: an overview. J Clin Pathol. 2020;73:697–705.CrossRefPubMed
7.
Zurück zum Zitat Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, SartoriValinotti JC, Bennani NN, Shah MV, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. The Mayo Clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019;94(10):2054–71. https://doi.org/10.1016/j.mayocp.2019.02.023.CrossRefPubMed Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Davidge-Pitts CJ, Hurtado MD, Ravindran A, SartoriValinotti JC, Bennani NN, Shah MV, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. The Mayo Clinic histiocytosis working group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019;94(10):2054–71. https://​doi.​org/​10.​1016/​j.​mayocp.​2019.​02.​023.CrossRefPubMed
9.
Zurück zum Zitat Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, Morlote DM, King RL, Rummage C, Zanwar S, Acosta-Medina AM, Tobin WO, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Witzig TE, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman Disease based on KRAS and MEK alteration status. JAMA Oncol. 2022;8(12):1816–20. https://doi.org/10.1001/jamaoncol.2022.4432.CrossRefPubMedPubMedCentral Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, Morlote DM, King RL, Rummage C, Zanwar S, Acosta-Medina AM, Tobin WO, Shah MV, Bennani NN, Vassallo R, Ryu JH, Koster MJ, Davidge-Pitts CJ, Witzig TE, Goyal G, Go RS, Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group. Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman Disease based on KRAS and MEK alteration status. JAMA Oncol. 2022;8(12):1816–20. https://​doi.​org/​10.​1001/​jamaoncol.​2022.​4432.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Arun VP. Primary skeletal Rosai Dorfman disease of distal tibia. J Orthop Oncol. 2021;7:151. Arun VP. Primary skeletal Rosai Dorfman disease of distal tibia. J Orthop Oncol. 2021;7:151.
19.
Zurück zum Zitat Joshi V, Offer G, Richards C, Rathinam S. Chest wall resection and reconstruction for Rosai-Dorfman Disease masquerading as a chest wall sarcoma. Ann R Coll Surg Eng. 2018;100:e28-30.CrossRef Joshi V, Offer G, Richards C, Rathinam S. Chest wall resection and reconstruction for Rosai-Dorfman Disease masquerading as a chest wall sarcoma. Ann R Coll Surg Eng. 2018;100:e28-30.CrossRef
22.
Zurück zum Zitat La Barge III, DV, Salzman KL, Harnsberger HR, Ginsberg LE, Hamilton BE, Wiggins III HR, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): imaging manifestations in the head and neck. AJR. 2008;191:W299-306.CrossRefPubMed La Barge III, DV, Salzman KL, Harnsberger HR, Ginsberg LE, Hamilton BE, Wiggins III HR, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): imaging manifestations in the head and neck. AJR. 2008;191:W299-306.CrossRefPubMed
23.
Zurück zum Zitat Xu Q, Fu L, Liu C. Multimodality imaging-based evaluation of Rosai-Dorfman disease in the head and neck: a retrospective observational study. Medicine (Baltimore). 2017;96:e9372.CrossRefPubMed Xu Q, Fu L, Liu C. Multimodality imaging-based evaluation of Rosai-Dorfman disease in the head and neck: a retrospective observational study. Medicine (Baltimore). 2017;96:e9372.CrossRefPubMed
24.
Zurück zum Zitat Hingwala D, Neelima R, Kesavadas C, et al. Advanced MRI in Rosai-Dorfman disease: correlation with histopathology. J Neuroradiol. 2011;38:113–7.CrossRefPubMed Hingwala D, Neelima R, Kesavadas C, et al. Advanced MRI in Rosai-Dorfman disease: correlation with histopathology. J Neuroradiol. 2011;38:113–7.CrossRefPubMed
25.
Zurück zum Zitat Thomas B, Somasundaram S, Thamburaj K, Kesavadas C, Gupta AK, Bodhey NK, et al. Clinical applications of susceptibility weighted MR imaging of the brain - a pictorial review. Neuroradiology. 2008;50:10e516.CrossRef Thomas B, Somasundaram S, Thamburaj K, Kesavadas C, Gupta AK, Bodhey NK, et al. Clinical applications of susceptibility weighted MR imaging of the brain - a pictorial review. Neuroradiology. 2008;50:10e516.CrossRef
Metadaten
Titel
Extranodal Rosai-Dorfman Disease: a rare presentation involving anterior chest wall in a middle-aged female
verfasst von
Abhimanyu Agarwal
Aishwarya Ravindran
James Donahue
Isam-Eldin Eltoum
Mostafa Abozeed
Publikationsdatum
21.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 3/2024
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-023-04427-z

Weitere Artikel der Ausgabe 3/2024

Skeletal Radiology 3/2024 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.